Private: Image Post Format


Effective June 1, 2016, the Nova Scotia Pharmacare will begin funding INFLECTRA™ (infliximab) as an exception status benefit. For infliximab-naïve patients whose infliximab therapy is initiated after June 1, 2016, Inflectra will be the product approved for the following indications: Rheumatoid Arthritis Ankylosing Spondylitis Psoriasis Criteria Updates – Rheumatoid Arthritis The Atlantic ... Read More


The final phase of Nova Scotia’s Fair Drug Pricing, bringing the price the province pays for generic drugs down to 35 per cent of the relevant brand price, goes into effect in the province today. This is the last of the three-step phase-in of the policy that began in July ... Read More